These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 2171608

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
    Kidokoro-Kunii Y, Emoto N, Cho K, Oikawa S.
    J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
    Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MM, Panzan AD, Facuri FV, Etchebehere EC, Lima MC, Tambascia MA, Camargo EE.
    Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Prediction of remission in Graves' disease after thionamide therapy by technetium-99m early uptake].
    Misaki T, Dokoh S, Koh T, Shimbo S, Hidaka A, Iida Y, Kasagi K, Konishi J.
    Kaku Igaku; 1991 Feb; 28(2):157-61. PubMed ID: 1711131
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pertechnetate thyroid uptake is not always suppressed in patients with subacute thyroiditis.
    Shigemasa C, Teshima S, Taniguchi S, Ueta Y, Mitani Y, Yoshida A.
    Clin Nucl Med; 1997 Feb; 22(2):109-14. PubMed ID: 9031769
    [Abstract] [Full Text] [Related]

  • 12. Thyroid blood flow and uptake of technetium-99m pertechnetate in Graves' disease.
    Sekulić V, Rajić M, Vlajković M, Ilić S, Bogićević M, Antić S, Dimić D.
    Hell J Nucl Med; 2006 Feb; 9(3):173-6. PubMed ID: 17160158
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison between peak systolic velocity of the inferior thyroid artery and technetium-99m pertechnetate thyroid uptake in differentiating Graves' disease from thyroiditis.
    Malik SA, Choh NA, Misgar RA, Khan SH, Shah ZA, Rather TA, Shehjar F, Laway BA.
    Arch Endocrinol Metab; 2019 Feb; 63(5):495-500. PubMed ID: 31482952
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators.
    Prakash R.
    Eur J Nucl Med; 1996 Feb; 23(2):118-22. PubMed ID: 8925844
    [Abstract] [Full Text] [Related]

  • 18. Graves' disease: thyroid function and immunologic activity.
    Gossage AA, Crawley JC, Copping S, Hinge D, Himsworth RL.
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K, Yamazaki K, Yamada E, Kanaji Y, Miura M, Obara T.
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.